Neuropathobiology of non-motor symptoms in Parkinson disease

Journal of Neural Transmission

Volumn 122, Issue 10, 2015, Pages 1429-1440

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Brainstem; Non motor features; Parkinson disease; Synuclein pathology

Indexed keywords

ALPHA SYNUCLEIN;

ABNORMAL SENSATION; AGGRESSIVENESS; ANHIDROSIS; ANXIETY DISORDER; APATHY; BEHAVIOR DISORDER; BLURRED VISION; BRAIN REGION; CLINICAL FEATURE; COGNITIVE DEFECT; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIPLOPIA; DIZZINESS; DOPAMINERGIC SYSTEM; DRY EYE; DYSAUTONOMIA; DYSLEXIA; DYSPHAGIA; DYSPNEA; FAINTNESS; FATIGUE; HALLUCINATION; HEARING IMPAIRMENT; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; HYPOSMIA; IMPOTENCE; INSOMNIA; LEWY BODY; MICROGRAPHIA; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NOCTURIA; NONHUMAN; NONMOTOR SYMPTOM; ORTHOSTATIC HYPOTENSION; PAIN; PARASOMNIA; PARKINSON DISEASE; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; SEBORRHEA; STRIDOR; URINARY FREQUENCY; URINARY URGENCY; ANIMAL; BRAIN; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; PARKINSON DISEASE;

EID: 84942990024     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-015-1405-5     Document Type: Review

References (185)

1. Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 24:2175–2186
2. Aho L, Parkkinen L, Pirttila T, Alafuzoff I (2008) Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects. Dement Geriatr Cogn Disord 25:423–432
3. Akhtar RS, Stern MB (2012) New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications. Expert Rev Neurother 12:1429–1438
4. Almeida TF, Roizenblatt S, Tufik S (2004) Afferent pain pathways: a neuroanatomical review. Brain Res 1000:40–56
5. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H (2005) Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 15:29–34
6. Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S, Greene JG (2007) Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp Neurol 207:4–12
7. Archibald NK, Clarke MP, Mosimann UP, Burn DJ (2009) The retina in Parkinson’s disease. Brain 132:1128–1145
8. Attems J, Walker L, Jellinger KA (2014) Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol 127:459–475
9. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG (2009a) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613–634
10. Beach TG, White CL 3rd, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH (2009b) Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol 117:169–174
11. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG (2010) Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119:689–702
12. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N (2014) Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett 571:34–38
13. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455
14. Blandini F, Balestra B, Levandis G, Cervio M, Greco R, Tassorelli C, Colucci M, Faniglione M, Bazzini E, Nappi G, Clavenzani P, Vigneri S, De Giorgio R, Tonini M (2009) Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson’s disease. Neurosci Lett 467:203–207
15. Bloch A, Probst A, Bissig H, Adams H, Tolnay M (2006) Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 32:284–295
16. Blonder LX, Slevin JT (2011) Emotional dysfunction in Parkinson’s disease. Behav Neurol 24:201–217
17. Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S (2014) Alpha-synuclein in the inner retina in parkinson disease. Ann Neurol 75:964–966
18. Boeve BF (2010) REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci 1184:15–54
19. Boeve BF, Silber MH, Ferman TJ, Kokmen E, Smith GE, Ivnik RJ, Parisi JE, Olson EJ, Petersen RC (1998) REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 51:363–370
20. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, Caselli RC, Tippman-Peikert M, Olson EJ, Lin SC, Young T, Wszolek Z, Schenck CH, Mahowald MW, Castillo PR, Del Tredici K, Braak H (2007) Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130:2770–2788
21. Braak H, Del Tredici K (2008) Nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925
22. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
23. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA (2005) Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64:1404–1410
24. Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396:67–72
25. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K (2007) Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 113:421–429
26. Breen KC, Drutyte G (2013) Non-motor symptoms of Parkinson’s disease: the patient’s perspective. J Neural Transm 120:531–535
27. Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 64:485–491
28. Burn DJ (2010) Dementia in Parkinson’s disease. In: Schapira AHV, Lang AET, Fahn S (eds) Movement Disorders 4. Saunders-Elsevier, Philadelphia, pp 188–212
29. Cersosimo MG, Benarroch EE (2008) Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 23:1065–1075
30. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464–474
31. Chaudhuri KR, Tolosa E, Schapira A, Poewe W (eds) (2009) Non-motor symptoms of parkinson’s disease. Oxford Univ. Press, Oxford
32. Chaudhuri KR, Tolosa E, Schapira A, Poewe W (eds) (2014) Non-motor symptoms of Parkinson’s disease, 2nd edn. Oxford Univ. Press, Oxford
33. Chaumette T, Lebouvier T, Aubert P, Lardeux B, Qin C, Li Q, Accary D, Bezard E, Bruley des Varannes S, Derkinderen P, Neunlist M (2009) Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol Motil 21:215–222
34. Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67:715–725
35. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF (2010) REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 75:494–499
36. Colosimo C, Hughes AJ, Kilford L, Lees AJ (2003) Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:852–856
37. Colosimo C, Morgante L, Antonini A, Barone P, Avarello TP, Bottacchi E, Cannas A, Ceravolo MG, Ceravolo R, Cicarelli G, Gaglio RM, Giglia L, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P, Simoni L, Marconi R (2010) Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 257:5–14
38. Dabby R, Djaldetti R, Shahmurov M, Treves TA, Gabai B, Melamed E, Sadeh M, Avinoach I (2006) Skin biopsy for assessment of autonomic denervation in Parkinson’s disease. J Neural Transm 113:1169–1176
39. Defazio G, Berardelli A, Fabbrini G, Martino D, Fincati E, Fiaschi A, Moretto G, Abbruzzese G, Marchese R, Bonuccelli U, Del Dotto P, Barone P, De Vivo E, Albanese A, Antonini A, Canesi M, Lopiano L, Zibetti M, Nappi G, Martignoni E, Lamberti P, Tinazzi M (2008) Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 65:1191–1194
40. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119:703–713
41. DelleDonne A, Klos KJ, Fujishiro H, Ahmed Z, Parisi JE, Josephs KA, Frigerio R, Burnett M, Wszolek ZK, Uitti RJ, Ahlskog JE, Dickson DW (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 65:1074–1080
42. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord 15(Suppl 3):S1–S5
43. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y (2010) Evidence in favor of Braak staging of Parkinson’s disease. Mov Disord 25(Suppl 1):S78–S82
44. Djaldetti R, Lev N, Melamed E (2009) Lesions outside the CNS in Parkinson’s disease. Mov Disord 24:793–800
45. Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C (2014) Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol 128:99–109
46. Drolet RE, Cannon JR, Montero L, Greenamyre JT (2009) Chronic rotenone exposure reproduces Parkinson’s disease gastrointestinal neuropathology. Neurobiol Dis 36:96–102
47. Duda JE (2010) Olfactory system pathology as a model of Lewy neurodegenerative disease. J Neurol Sci 289:49–54
48. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707 quiz 1837
49. Feldmann A, Illes Z, Kosztolanyi P, Illes E, Mike A, Kover F, Balas I, Kovacs N, Nagy F (2008) Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord 23:42–46
50. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M (2010) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 118:821–839
51. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF (2008) Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28:247–256
52. Forno LS (1969) Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 17:557–575
53. Fumimura Y, Ikemura M, Saito Y, Sengoku R, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, Mizusawa H, Murayama S (2007) Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol 66:354–362
54. Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, Lerche S, Eschweiler GW, Maetzler W, Berg D (2014) Prodromal features for Parkinson’s disease–baseline data from the TREND study. Eur J Neurol 21:766–772
55. Gaig C, Tolosa E (2009) When does Parkinson’s disease begin? Mov Disord 24(Suppl 2):S656–S664
56. Gallagher DA, Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 46:581–589
57. Gallagher DA, Lees AJ, Schrag A (2010) What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 25:2493–2500
58. Gerlach M, Maetzler W, Broich K, Hampel H, Rems L, Reum T, Riederer P, Stoffler A, Streffer J, Berg D (2012) Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics. J Neural Transm 119:39–52
59. Ghebremedhin E, Del Tredici K, Langston JW, Braak H (2009) Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson’s disease: an anatomical study. Acta Neuropathol 118:777–784
60. Goetz CG, Emre M, Dubois B (2008) Parkinson’s disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 64(Suppl 2):S81–S92
61. Greene JG, Noorian AR, Srinivasan S (2009) Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson’s disease. Exp Neurol 218:154–161
62. Grinberg LT, Rueb U, Alho AT, Heinsen H (2010) Brainstem pathology and non-motor symptoms in PD. J Neurol Sci 289:81–88
63. Haas BR, Stewart TH, Zhang J (2012) Premotor biomarkers for Parkinson’s disease—a promising direction of research. Transl Neurodegener 1:11
64. Halliday G, Murphy K (2010) Pathology of Parkinson’s disease. In: Schapira AHV, Lang AET, Fahn S (eds) Movement disorders 4. Saunders-Elsevier, Philadelphia, pp 132–154
65. Hawkes CH, Del Tredici K, Braak H (2010) A timeline for Parkinson’s disease. Parkinsonism Relat Disord 16:79–84
66. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844
67. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T, Wang ZY, Roybon L, Melki R, Li JY (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 128:805–820
68. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916–1921
69. Iijima M, Osawa M, Momose M, Kobayakawa T, Saito S, Iwata M, Uchiyama S (2010) Cardiac sympathetic degeneration correlates with olfactory function in Parkinson’s disease. Mov Disord 25:1143–1149
70. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, Murayama S (2008) Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67:945–953
71. Ince PG, McArthur FK, Bjertness E, Torvik A, Candy JM, Edwardson JA (1995) Neuropathological diagnoses in elderly patients in Oslo: Alzheimer’s disease, Lewy body disease, vascular lesions. Dementia 6:162–168
72. Iranzo A, Tolosa E (2009) REM sleep behaviour disorder in Parkinson’s disease. In: Chaudhuri KR, Tolosa E, Schapira A, Poewe W (eds) Non-motor symptoms of Parkinson’s disease. Oxford Univ. Press, Oxford, pp 177–193
73. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, Tolosa E (2006) Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5:572–577
74. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology 52:1269–1271
75. Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235
76. Jellinger KA (2006) The morphological basis of mental dysfunction in Parkinson’s disease. J Neurol Sci 248:167–172
77. Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16
78. Jellinger KA (2009a) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792:730–740
79. Jellinger KA (2009b) Formation and development of Lewy pathology: a critical update. J Neurol 256(Suppl 3):270–279
80. Jellinger KA (2010) The neuropathologic substrate of Parkinson disease dementia. Acta Neuropathol 119:151–153
81. Jellinger KA (2011) Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 310:107–111
82. Jellinger KA (2012a) Neurobiology of cognitive impairment in Parkinson’s disease. Expert Rev Neurother 12:1451–1466
83. Jellinger KA (2012b) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 27:8–30
84. Jellinger KA (2012c) The role of alpha-synuclein in neurodegeneration—an update. Translat Neurosci 3:75–122
85. Jellinger KA (2013) Mild cognitive impairment in Parkinson disease: heterogenous mechanisms. J Neural Transm 120:157–167
86. Jellinger KA (2014) Neuropathology of Parkinson’s disease. In: Thomas M (ed) Inflammation in Parkinson’s disease: scientific and clinical aspects. Springer, New York, pp 25–74
87. Juri C, Rodriguez-Oroz M, Obeso JA (2010) The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci 289:60–65
88. Kalaitzakis ME, Pearce RK (2009) The morbid anatomy of dementia in Parkinson’s disease. Acta Neuropathol 118:587–598
89. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008a) Controversies over the staging of alpha-synuclein pathology in Parkinson’s disease. Acta Neuropathol 116:125–128 author reply 129–131
90. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008b) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34:284–295
91. Karasawa H, Pietra C, Giuliano C, Garcia-Rubio S, Xu X, Yakabi S, Tache Y, Wang L (2014) New ghrelin agonist, HM01 alleviates constipation and l-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson’s disease. Neurogastroenterol Motil 26:1771–1782
92. Kasten M, Kertelge L, Bruggemann N, van der Vegt J, Schmidt A, Tadic V, Buhmann C, Steinlechner S, Behrens MI, Ramirez A, Binkofski F, Siebner H, Raspe H, Hagenah J, Lencer R, Klein C (2010) Nonmotor symptoms in genetic Parkinson disease. Arch Neurol 67:670–676
93. Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9:1200–1213
94. Kim YK, Yoon IY, Kim JM, Jeong SH, Kim KW, Shin YK, Kim BS, Kim SE (2010) The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur J Neurol 17:487–492
95. Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, Ayling H, Kallis C, Sterlacci W, Maeir H, Poewe W, Lees AJ (2010) Brain stem pathology in Parkinson’s disease: an evaluation of the Braak staging model. Mov Disord 25:2508–2515
96. Korczyn AD, Gurevich T (2010) Parkinson’s disease: before the motor symptoms and beyond. J Neurol Sci 289:2–6
97. Kovacs GG, Milenkovic IJ, Preusser M, Budka H (2008) Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord 23:1608–1612
98. Kuo YM, Li Z, Jiao Y, Gaborit N, Pani AK, Orrison BM, Bruneau BG, Giasson BI, Smeyne RJ, Gershon MD, Nussbaum RL (2010) Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 19:1633–1650
99. Lang AE (2011) A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 26:775–783
100. Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339:1044–1053
101. Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, N’Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, Galmiche JP, Damier P, Derkinderen P (2010) Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS One 5:e12728
102. Lerche S, Seppi K, Behnke S, Liepelt-Scarfone I, Godau J, Mahlknecht P, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Poewe W, Berg D (2014) Risk factors and prodromal markers and the development of Parkinson’s disease. J Neurol 261:180–187
103. Lerche S, Brockmann K, Wurster I, Gaenslen A, Roeben B, Holz D, Eschweiler GW, Maetzler W, Berg D (2015) Reasons for mild parkinsonian signs—which constellation may indicate neurodegeneration? Parkinsonism Relat Disord 21:126–130
104. Liepelt-Scarfone I, Behnke S, Godau J, Schweitzer KJ, Wolf B, Gaenslen A, Berg D (2011) Relation of risk factors and putative premotor markers for Parkinson’s disease. J Neural Transm 118:579–585
105. Lim SY, Fox SH, Lang AE (2009) Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66:167–172
106. Lo RY, Tanner CM, Albers KB, Leimpeter AD, Fross RD, Bernstein AL, McGuire V, Quesenberry CP, Nelson LM, Van Den Eeden SK (2009) Clinical features in early Parkinson disease and survival. Arch Neurol 66:1353–1358
107. Mahlknecht P, Poewe W (2013) Defining premotor Parkinson’s disease: a window of opportunity for neuroprotection? Neurodegen Dis Manage 3:61–70
108. Mahlknecht P, Seppi K, Stockner H, Nocker M, Scherfler C, Kiechl S, Willeit J, Schmidauer C, Gasperi A, Rungger G, Poewe W (2013) Substantia nigra hyperechogenicity as a marker for Parkinson’s disease: a population-based study. Neurodegener Dis 12:212–218
109. Marder K (2010) Cognitive impairment and dementia in Parkinson’s disease. Mov Disord 25(Suppl 1):S110–S116
110. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629
111. Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2015) Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol 22:37–43
112. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M (2000) Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 100:285–290
113. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474
114. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, Ortega-Moreno A, Rebollo AC, Gomez-Rio M, Concha A, Munoz DG (2007) Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology 68:2012–2018
115. Morley JF, Pawlowski SM, Kesari A, Maina I, Pantelyat A, Duda JE (2014) Motor and non-motor features of Parkinson’s disease that predict persistent drug-induced Parkinsonism. Parkinsonism Relat Disord 20:738–742
116. Muller CM, de Vos RA, Maurage CA, Thal DR, Tolnay M, Braak H (2005) Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability. J Neuropathol Exp Neurol 64:623–628
117. Nolano M, Provitera V, Estraneo A, Selim MM, Caporaso G, Stancanelli A, Saltalamacchia AM, Lanzillo B, Santoro L (2008) Sensory deficit in Parkinson’s disease: evidence of a cutaneous denervation. Brain 131:1903–1911
118. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A (2012) Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72:893–901
119. Oinas M, Paetau A, Myllykangas L, Notkola IL, Kalimo H, Polvikoski T (2010) alpha-Synuclein pathology in the spinal cord autonomic nuclei associates with alpha-synuclein pathology in the brain: a population-based Vantaa 85 + study. Acta Neuropathol 119:715–722
120. Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K (2004) Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies. Pathol Int 54:682–687
121. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H (2005) Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109:583–588
122. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H (2007a) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113:81–86
123. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H (2007b) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17:24–30
124. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain 131:642–650
125. O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord 23:101–106
126. Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3:591–605
127. Pan-Montojo FJ, Funk RH (2010) Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system. J Vis Exp 26(44). doi:10.3791/2123
128. Pan-Montojo F, Reichmann H (2014) Considerations on the role of environmental toxins in idiopathic Parkinson’s disease pathophysiology. Transl Neurodegener 3:10
129. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH (2010) Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5:e8762
130. Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I (2005) Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25:304–314
131. Parkkinen L, Pirttila T, Alafuzoff I (2008) Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407
132. Perry RH, Irving D, Tomlinson BE (1990) Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci 100:223–233
133. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL (2008) Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience 153:733–750
134. Poewe W (2008) Non-motor symptoms in Parkinson’s disease. Eur J Neurol 15(Suppl 1):14–20
135. Ponsen MM, Stoffers D, Wolters E, Booij J, Berendse HW (2010) Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry 81:396–399
136. Postuma RB, Lanfranchi PA, Blais H, Gagnon JF, Montplaisir JY (2010) Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord 25:2304–2310
137. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY (2011) Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 69:811–818
138. Prediger RD, Matheus FC, Schwarzbold ML, Lima MM, Vital MA (2012) Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology 62:115–124
139. Probst A, Bloch A, Tolnay M (2008) New insights into the pathology of Parkinson’s disease: does the peripheral autonomic system become central? Eur J Neurol 15(Suppl 1):1–4
140. Przuntek H, Muller T, Riederer P (2004) Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm 111:201–216
141. Riederer P, Sian-Hulsmann J (2012) The significance of neuronal lateralisation in Parkinson’s disease. J Neural Transm 119:953–962
142. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38:277–301
143. Riederer P, Rausch WD, Birkmayer W, Jellinger K, Danielczyk W (1978a) Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson’s disease and in liver cirrhosis. J Neural Transm Suppl 14:153–161
144. Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978b) CNS Modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm Suppl 14:121–131
145. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139
146. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG (2009) Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 23:295–297
147. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T (2008) Bladder and bowel dysfunction in Parkinson’s disease. J Neural Transm 115:443–460
148. Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, Bharucha AE, Rocca WA (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73:1752–1758
149. Savica R, Rocca WA, Ahlskog JE (2010) When does Parkinson disease start? Arch Neurol 67:798–801
150. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120:131–143
151. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, Arai T, Sawabe M, Tanaka N, Mochizuki H, Inoue K, Murayama S (2008) Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 67:1072–1083
152. Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, Jelebinkov M, Kurdi Y, Ebadi M (2013) Biomarkers in Parkinson’s disease (recent update). Neurochem Int 63:201–229
153. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ (2002) Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 8:193–197
154. Siderowf A, Stern MB (2008) Premotor Parkinson’s disease: clinical features, detection, and prospects for treatment. Ann Neurol 64(Suppl 2):S139–S147
155. Silveira-Moriyama L, Holton JL, Kingsbury A, Ayling H, Petrie A, Sterlacci W, Poewe W, Maier H, Lees AJ, Revesz T (2009) Regional differences in the severity of Lewy body pathology across the olfactory cortex. Neurosci Lett 453:77–80
156. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, Quigley EM (1995) Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet 346:861–864
157. Sone M, Yoshida M, Hashizume Y, Hishikawa N, Sobue G (2005) Alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol 110:19–26
158. Song Y, Gu Z, An J, Chan P (2014) Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson’s disease. Neurol Sci 35:1991–1996
159. Sonnen JA, Postupna N, Larson EB, Crane PK, Rose SE, Montine KS, Leverenz JB, Montine TJ (2010) Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 20:654–659
160. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ (2007) Dopamine transporter relation to dopamine turnover in Parkinson’s disease: a positron emission tomography study. Ann Neurol 62:468–474
161. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
162. Sprenger F, Poewe W (2013) Management of motor and non-motor symptoms in Parkinson’s disease. CNS Drugs 27:259–272
163. Stemberger S, Poewe W, Wenning GK, Stefanova N (2010) Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol 224:459–464
164. Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137
165. Sung HY, Kim JS, Lee KS, Kim YI, Song IU, Chung SW, Yang DW, Cho YK, Park JM, Lee IS, Kim SW, Chung IS, Choi MG (2010) The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson’s disease. Mov Disord 25:2361–2368
166. Tachibana N (2009) Historical overview of REM sleep behavior disorder in relation to its pathophysiology. Brain Nerve 61:558–568
167. Tan SK, Hartung H, Sharp T, Temel Y (2011) Serotonin-dependent depression in Parkinson’s disease: a role for the subthalamic nucleus? Neuropharmacology 61:387–399
168. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW (2009) Nonmotor symptoms of Parkinson’s disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29:8103–8113
169. Tian YM, Chen X, Luo DZ, Zhang XH, Xue H, Zheng LF, Yang N, Wang XM, Zhu JX (2008) Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson’s disease. Neuroscience 153:634–644
170. Tolosa E, Gaig C, Santamaria J, Compta Y (2009) Diagnosis and the premotor phase of Parkinson disease. Neurology 72:S12–S20
171. Tolosa E, Santamaria J, Gaig C, Compta Y (2010) Nonmotor aspects of Parkinson’s disease. In: Schapira AHV, Lang AET, Fahn S (eds) Movement disorders 4. Saunders-Elsevier, Philadelphia, pp 229–251
172. Ugrumov MV, Khaindrava VG, Kozina EA, Kucheryanu VG, Bocharov EV, Kryzhanovsky GN, Kudrin VS, Narkevich VB, Klodt PM, Rayevsky KS, Pronina TS (2011) Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience 181:175–188
173. van Rooden SM, Colas F, Martinez-Martin P, Visser M, Verbaan D, Marinus J, Chaudhuri RK, Kok JN, van Hilten JJ (2011) Clinical subtypes of Parkinson’s disease. Mov Disord 26:51–58
174. Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 38(Suppl 2):2–7
175. Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H (2010) Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 120:1–12
176. Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T (2003) Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol 106:374–382
177. Wang L, Fleming SM, Chesselet MF, Tache Y (2008) Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. NeuroReport 19:873–876
178. Weintraub D (2010) Psychiatric issues in Parkinson’s disease. In: Schapira AHV, Lang AET, Fahn S (eds) Movement disorders 4. Saunders-Elsevier, Philadelphia, pp 213–228
179. Witt M, Bormann K, Gudziol V, Pehlke K, Barth K, Minovi A, Hahner A, Reichmann H, Hummel T (2009) Biopsies of olfactory epithelium in patients with Parkinson’s disease. Mov Disord 24:906–914
180. Wolters E, Braak H (2006) Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm Suppl 309–319
181. Wood PB (2008) Role of central dopamine in pain and analgesia. Expert Rev Neurother 8:781–797
182. Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, Nakahara T, Miyamato N, Urabe T, Hattori N (2014) Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: any relationship with the cumulative doses of anti-parkinsonian medications? J Neurol Disord Stroke 2:1042
183. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70:1042–1048
184. Zhang H, Gu Z, An J, Wang C, Chan P (2014) Non-motor symptoms in treated and untreated Chinese patients with early Parkinson’s disease. Tohoku J Exp Med 232:129–136
185. Zheng LF, Wang ZY, Li XF, Song J, Hong F, Lian H, Wang Q, Feng XY, Tang YY, Zhang Y, Zhu JX (2011) Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson’s disease. Brain Res 1420:59–67